Turner White CommunicationsAbout TWCSubscribeContact TWCHomeSearch
Hospital PhysicianJCOMSMPBRMsCart
Current Contents
Where We Are Indexed
Past Issue Archives
Clinical Communication
In Review
Editorial Board
Information for Authors
Author Form

Reprints, Permissions, & Copyright
Site Map
BACK ISSUE articles are $15 each.
International credit cards NOT accepted.

JCOM Paid Subscribers
user name:
Forgot password?

JCOM Abstract

J Clin Outcomes Manage 
2009 May;16(5):215-223
Costs and utilization associated with imatinib adherence in patients with chronic myeloid leukemia or gastrointestinal stromal turmors
Halpern R, Barghout V, Zarotsky V, Williams DE

Abstract Objective: To analyze the relationship between imatinib compliance and costs and inpatient hospitalizations for patients with chronic myeloid leukemia (CML) or gastrointestinal stromal tumors (GIST). Design: Administrative claims–based retrospective cohort study. Setting and participants: Patients in a large national U.S. health plan with CML or GIST, 2 or more imatinib claims from 1 June 2001 to 31 March 2005, and a minimum 12-month follow-up after first imatinib claim. Main outcome measures: Adherence to medication (as measured by medication possession ratio) and association with Charlson Comorbidity Index score, total follow-up medical and health care (medical plus pharmacy) costs, inpatient hospitalizations, and length of stay (LOS). Results: 374 CML and 91 GIST patients were identified. Unadjusted mean medical costs and inpatient LOS were significantly and inversely associated with adherence level. Unadjusted total health care costs were inversely related to adherence within the CML cohort. Multivariate analysis showed that good adherence to imatinib, on average, was associated with $121,247 lower medical costs, $57,266 lower health care costs, 31.3 times fewer inpatient hospitalizations, and 9.1 times shorter LOS as compared with poor adherence. Patients with GIST (vs. CML) and those with higher Charlson Comorbidity Index scores had significantly higher medical and health care costs. Conclusion: Good adherence to imatinib was associated with substantially lower follow-up medical and health care costs relative to poor adherence, controlling for condition (ie, CML or GIST) and demographic and health factors.

Original Research

Search the Turner White index to find abstracts of articles published in JCOM.

New issues are posted one month following publication of the printed journal.

View past issue archives:    2013    2012    2011    2010    2009    2008    2007
   2006    2005    2004    2003     2002     2001     2000     1999

Hospital Physician     JCOM     Seminars in Medical Practice
Hospital Physician Board Review Manuals
About TWC    Subscribe    Contact TWC    Home    Search   Site Map

Copyright © 2018, Turner White Communications
Updated 1/20/14 • jdw